[go: up one dir, main page]

HUP0000587A1 - Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény - Google Patents

Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0000587A1
HUP0000587A1 HU0000587A HUP0000587A HUP0000587A1 HU P0000587 A1 HUP0000587 A1 HU P0000587A1 HU 0000587 A HU0000587 A HU 0000587A HU P0000587 A HUP0000587 A HU P0000587A HU P0000587 A1 HUP0000587 A1 HU P0000587A1
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
composition containing
containing tacrolimus
tacrolimus
surfactant
Prior art date
Application number
HU0000587A
Other languages
English (en)
Inventor
Takehisa Hata
Takeo Hirose
Sumihisa Kimura
Fumio Shimojo
Yuji Tokunaga
Satoshi Ueda
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of HUP0000587A1 publication Critical patent/HUP0000587A1/hu
Publication of HUP0000587A3 publication Critical patent/HUP0000587A3/hu
Publication of HU228680B1 publication Critical patent/HU228680B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

A találmány tárgya vízőldhatatlan gyógyászati hatóanyagőt, pl.:takőliműszt (FK 506) felületaktív anyagő(ka)t és szilárd hőrdőzó(ka)ttartalmazó gyógyszerkészítmény, mely javítőtt őldhatósági és őrálisfelszívódási tűlajdőnságőkkal rendelkezik. ŕ
HU0000587A 1996-12-06 1997-12-05 Pharmaceutical composition containing tacrolimus (fk506) HU228680B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32661896 1996-12-06
PCT/JP1997/004452 WO1998024418A1 (fr) 1996-12-06 1997-12-05 Compositions medicinales

Publications (3)

Publication Number Publication Date
HUP0000587A1 true HUP0000587A1 (hu) 2000-09-28
HUP0000587A3 HUP0000587A3 (en) 2001-12-28
HU228680B1 HU228680B1 (en) 2013-05-28

Family

ID=18189823

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000587A HU228680B1 (en) 1996-12-06 1997-12-05 Pharmaceutical composition containing tacrolimus (fk506)

Country Status (17)

Country Link
US (1) US6346537B1 (hu)
EP (1) EP0943327B1 (hu)
JP (1) JP4284706B2 (hu)
KR (1) KR20000057242A (hu)
CN (1) CN1149979C (hu)
AR (1) AR008927A1 (hu)
AT (1) ATE367150T1 (hu)
AU (1) AU726451B2 (hu)
BR (1) BR9713866A (hu)
CA (1) CA2274485C (hu)
DE (1) DE69737936T2 (hu)
ES (1) ES2286835T3 (hu)
HU (1) HU228680B1 (hu)
RU (1) RU2197226C2 (hu)
TW (1) TW426516B (hu)
WO (1) WO1998024418A1 (hu)
ZA (1) ZA9710927B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID27825A (id) 1998-03-26 2001-04-26 Fujisawa Pharmaceutical Co Sediaan lepas lambat
FR2781373B1 (fr) * 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
AU775694B2 (en) * 1999-03-11 2004-08-12 Fujisawa Pharmaceutical Co., Ltd. Liposome preparations
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
AUPR529701A0 (en) * 2001-05-28 2001-06-21 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
KR100486016B1 (ko) * 2003-07-09 2005-04-29 주식회사종근당 타크로리무스의 속용성 고체분산체 및 이의 제조방법
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
EP1663217B1 (en) * 2003-08-29 2010-07-07 LifeCycle Pharma A/S Solid dispersions comprising tacrolimus
ES2376238T3 (es) * 2003-08-29 2012-03-12 Veloxis Pharmaceuticals A/S Composiciones de liberación modificada comprendiendo tacrolimus.
KR100866728B1 (ko) * 2004-11-12 2008-11-03 주식회사종근당 타크로리무스를 함유하는 주사제
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
DE602006013826D1 (de) * 2005-07-20 2010-06-02 Peter Valent Zusammensetzungen zur behandlung von systemischer mastocytose
US7652364B2 (en) * 2005-12-21 2010-01-26 Teradata Us, Inc. Crossing conductive traces in a PCB
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CA3027598C (en) 2007-01-10 2020-07-21 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
KR100868295B1 (ko) * 2007-02-15 2008-11-11 풍림무약주식회사 레플루노미드를 함유하는 고체분산체 및 이의 제조방법
ES2634153T3 (es) 2007-05-30 2017-09-26 Veloxis Pharmaceuticals A/S Forma de dosificación oral de una vez al día que comprende tacrolimus
US12083103B2 (en) 2007-05-30 2024-09-10 Veloxis Pharmaceuticals, Inc. Tacrolimus for improved treatment of transplant patients
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
CN101580535B (zh) * 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
US12403095B2 (en) 2008-05-30 2025-09-02 Veloxis Pharmaceuticals, Inc. Stabilized tacrolimus composition
RU2373926C1 (ru) * 2008-06-06 2009-11-27 Сергей Юрьевич Лешков Композиции, содержащие частицы резвератрола, и способ их получения (варианты)
RU2574006C2 (ru) * 2008-07-08 2016-01-27 Лайфсайкл Фарма А/С Такролимус для улучшенного лечения пациентов с трансплантатами
JP2012502902A (ja) * 2008-09-17 2012-02-02 シージェイ チェルジェダン コーポレイション アデホビルジピボキシルの安定化した固体分散体及びその製造方法
LT2575769T (lt) * 2010-02-17 2016-10-10 Veloxis Pharmaceuticals A/S Stabilizuota takrolimuzo kompozicija
WO2011116034A1 (en) * 2010-03-17 2011-09-22 Lutran Industries, Inc. Human medicinal treatment and product typically based on salt of peroxymonosulfuric acid, and associated product fabrication
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CN105663092A (zh) * 2016-03-03 2016-06-15 海南华益泰康药业有限公司 一种含有他克莫司固体分散体的缓释胶囊及其制备方法
EP3463369A4 (en) 2016-05-26 2019-12-11 Dermala Inc. Compositions and methods for treating acne vulgaris

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
DE69016515T2 (de) 1989-07-05 1995-06-08 Fujisawa Pharmaceutical Co Wässriges flüssiges Mittel zur äusserlichen Anwendung.
US5215995A (en) 1989-10-16 1993-06-01 Fujisawa Pharmaceutical Co., Ltd. Hair revitalizing agent
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
CA2054983A1 (en) 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
US5817333A (en) 1991-10-31 1998-10-06 Fujisawa Pharmaceutical Co., Ltd. Liposome preparation containing a tricyclic compound
WO1994010981A1 (fr) 1992-11-18 1994-05-26 Fujisawa Pharmaceutical Co., Ltd. Preparation pharmaceutique a action prolongee
JPH07291854A (ja) * 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees

Also Published As

Publication number Publication date
WO1998024418A1 (fr) 1998-06-11
AR008927A1 (es) 2000-02-23
JP4284706B2 (ja) 2009-06-24
BR9713866A (pt) 2000-03-14
DE69737936T2 (de) 2007-12-06
KR20000057242A (ko) 2000-09-15
AU5136998A (en) 1998-06-29
EP0943327A4 (en) 2003-06-25
EP0943327A1 (en) 1999-09-22
TW426516B (en) 2001-03-21
EP0943327B1 (en) 2007-07-18
HUP0000587A3 (en) 2001-12-28
RU2197226C2 (ru) 2003-01-27
DE69737936D1 (de) 2007-08-30
ATE367150T1 (de) 2007-08-15
CN1149979C (zh) 2004-05-19
US6346537B1 (en) 2002-02-12
HU228680B1 (en) 2013-05-28
CA2274485A1 (en) 1998-06-11
ES2286835T3 (es) 2007-12-01
ZA9710927B (en) 1998-06-15
CN1245424A (zh) 2000-02-23
CA2274485C (en) 2008-02-05
AU726451B2 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
HUP0000587A1 (hu) Takrolimuszt (FK506) tartalmazó gyógyszerkészítmény
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
LT2000064A (en) Flash-melt oral dosage formulation
CA2259148A1 (en) Solid oral dosage forms of valsartan
DE69932835D1 (de) Medizinische aerosolzubereitung
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
HUP9900413A3 (en) Use of coralyne derivatives, new coralyne derivatives and use thereof, pharmaceutical compositions containing these new coralyne derivatives
CA2416403A1 (en) A medicinal aerosol formulation
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
CA2251886A1 (en) An oral pharmaceutical formulation containing ibandronate
CA2295035A1 (en) Pharmaceutical formulations containing voriconazole
DE60321774D1 (de) Aerosol-formulierungen von formoterol und mometason
DK0918507T3 (da) Aerosolformuleringer
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
HRP20010277B1 (hr) Farmaceutski pripravak koji sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
MY118569A (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
MY127350A (en) Flash-melt oral dose formulations
WO1998008517A3 (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
CA2497171A1 (en) Water stabilized medicinal aerosol formulation
HUP0002346A1 (hu) Emlősök elmezavarainak kezelésére szolgáló gyógyszerkészítmény
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
ES2172182T3 (es) Composiciones farmaceuticas que comprenden cefuroxima axetil.
GEP20043377B (en) Pharmaceutical Complex
RU93004785A (ru) Твердые капсулы окфосфата цитарабина

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

MM4A Lapse of definitive patent protection due to non-payment of fees